Metabolic Syndrome Management

Introduction to Metabolic Syndrome

Metabolic syndrome is characterized by a variable combination of visceral obesity, alterations in glucose metabolism, lipid metabolism, and blood pressure, with high prevalence in middle-aged and elderly populations 1, 2
Patients with metabolic syndrome have higher prevalence of microalbuminuria, left ventricular hypertrophy, and arterial stiffness compared to those without the syndrome 1
The syndrome significantly increases cardiovascular risk and chance of developing diabetes 3

The European Society of Cardiology recommends aiming for 7-10% reduction in body weight over 6-12 months through modest caloric reduction (500-1000 calories/day) 1, 4
Reduce intake of saturated fats, trans-fatty acids, cholesterol, and simple carbohydrates, and increase consumption of fruits, vegetables, and whole grains 1, 2
Implement regular exercise with minimum 30 minutes of daily moderate physical activity 1, 2
Combine aerobic exercise with strength training for optimal results 4, 3

The European Heart Society recommends that when hypertension is present, drug treatment should start with a renin-angiotensin system blocker (ACE inhibitor or ARB) 1, 2, 5
Statins should be given for dyslipidemia 1, 2
Metformin is recommended for patients with impaired glucose tolerance or diabetes 1
SGLT2 inhibitors are emerging as first-line agents for cardiorenal metabolic syndrome due to their benefits in reducing cardiovascular events 6

Diagnostic procedures should include more in-depth assessment of subclinical organ damage in patients with metabolic syndrome 1
Ambulatory and home blood pressure monitoring is recommended 1
Treatment should address all components simultaneously for maximum cardiovascular risk reduction, according to the European Heart Society 1, 2

Beta-blockers should be avoided unless specifically indicated due to their adverse effects on glucose metabolism and lipid profile 1, 5
Chlorthalidone and other thiazide diuretics may cause small increases in fasting glucose but have shown good cardiovascular outcomes in patients with metabolic syndrome 5
Combination therapy with a renin-angiotensin system blocker and calcium antagonist has been associated with lower incidence of diabetes than conventional treatment with beta-blockers 7